Corteva Stock Earnings Reports

Corteva reported a strong start to 2026 with Q1 operating EBITDA up 21% and ~240 bps of margin expansion driven by price/mix, volume and cost productivity across both Seed and Crop Protection (CP). Organic sales rose ~7% (Seed +9%, CP +4%), with notable volume strength in new products, Spinosyns and North American seed (partly timing-driven). Management reaffirmed full-year guidance: operating EBITDA $4.0–4.2B, operating EPS $3.45–3.70 and margins ~22–23%, and expects mid-single-digit volume growth for Corteva overall. Key strategic updates: the seed/genetics business will be named Vylor and management expects to cross into royalty-positive territory later this year as licensing (PowerCore/Enlist) ramps; the separation of the two companies remains on track for Q4 with net dis-synergies trending better than the prior $100M estimate (guidance includes $50M of dis-synergies). Capital allocation and balance-sheet moves include a board-approved $1.5B discretionary pension contribution (to support investment-grade profiles for the separated entities) and a plan to repurchase ~$500M of shares in H1. Near-term headwinds called out: higher oil prices (modeled as a ~$40M headwind, mainly back half), tariff exposure (trending slightly more favorable than February assumptions), and geopolitical risks in the Middle East being monitored. Regional highlights: continued push to expand Enlist adoption in the U.S. (~65% projected soybean penetration) and an explicit focus on growing soybean trait penetration in Brazil (trait penetration entering double digits). Management emphasized progress in biologicals and new CP actives pipeline, ongoing cost/productivity capture, and the company’s biofuels-related opportunities as additional growth optionality. Management reiterated that the business should be assessed on a H1/H2 basis given seasonal timing shifts and that they will provide further detail at the September Investor Day.